Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib

Criteria

Inclusion Criteria:

• Diagnosis of reduced hepatic function (Child Pugh Classification A or B)

• Body Mass Index of 18-32 kg/m2

Exclusion Criteria:

• History of febrile illness within 5 days prior to first dose

• Any condition possibly affecting drug absorption (e.g. gastrectomy)

• Positive urine drug screen